Denali Therapeutics Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. Although the request references 2023 Q4, this filing reports full-year results; it does not provide a clear standalone fourth-quarter income statement or cash-flow summary.
Business context
Denali is a clinical-stage biopharmaceutical company developing therapies for neurodegenerative and lysosomal storage diseases. Its portfolio centers on Transport Vehicle technology intended to deliver medicines across the blood-brain barrier. The company had seven clinical-stage candidates across seven indications, no approved products, and no product-sales revenue.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Collaboration revenue | $330.5 million | $108.5 million |
| Research and development expense | $423.9 million | $358.7 million |
| General and administrative expense | $103.4 million | $90.5 million |
| Operating loss | $196.7 million | $340.7 million |
| Net loss | $145.2 million | $326.0 million |
| Net loss per share, basic and diluted | $1.06 | $2.60 |
| Net cash used in operating activities | $358.0 million | $244.7 million |
Revenue rose by $222.1 million, primarily because Denali recognized $293.9 million in April 2023 when Biogen exercised its option for the ATV:Abeta program. The company remained loss-making; the improvement in net loss also reflected higher interest and investment income ($51.5 million, versus $14.8 million). Approximate operating and net-loss margins were negative 59% and 44%, respectively, based on reported collaboration revenue.
At year-end, cash and cash equivalents were $127.1 million and short-term marketable securities were $907.4 million, totaling approximately $1.03 billion. Current assets were $1.064 billion and current liabilities $78.0 million. Total liabilities were $123.0 million, including $52.2 million of operating lease liabilities; the filing reports no borrowings. Stockholders’ equity was $1.031 billion. Management said existing cash, cash equivalents and marketable securities were expected to fund projected operations through at least the twelve months following the filing date, subject to assumptions and risks.
Operating cash use increased year over year, with the filing citing, among other factors, the reduction in Biogen-related contract liabilities after the option exercise. Investing cash flow was positive $249.3 million, largely reflecting marketable-security maturities and sales exceeding purchases; financing cash flow was positive $17.8 million, mainly from equity-plan exercises.
Material changes and operating developments
- R&D expense increased 18%, led by DNL310 development, including a $30.0 million F-star contingent-consideration charge and higher clinical-trial costs. Increased DNL343 trial costs and Biogen LRRK2 cost-sharing payments also contributed.
- Denali and Biogen revised the BIIB122/DNL151 development plan to focus on a timely efficacy readout in early Parkinson’s disease; the change was described as driven by timeline and resource priorities, not safety or efficacy results. In January 2024, a third party agreed to provide $75.0 million for a planned Phase 2a study in people with pathogenic LRRK2 variants; $12.5 million was received in January.
- Denali announced an intended spinout of its preclinical small-molecule portfolio in January 2024; it planned to retain its clinical-stage small-molecule programs.
- Common shares outstanding increased from 136.0 million at year-end 2022 to 138.4 million at year-end 2023. Stock-based compensation expense was $108.1 million.
Outlook, clinical updates and risks
- DNL310 for Hunter syndrome: In interim Phase 1/2 data reported in February 2024, mean CSF heparan sulfate reductions were approximately 90% at weeks 24, 49 and 104. The company also reported biomarker and exploratory clinical findings and said treatment was generally well tolerated. These are interim results, not evidence of regulatory approval. The global Phase 2/3 COMPASS study was enrolling; Denali expected to complete enrollment in 2024 and planned additional interim data presentations.
- DNL343 for ALS: The Phase 2/3 HEALEY ALS Platform Trial was recruiting. Prior 28-day Phase 1b results in 28 participants with ALS showed general tolerability, CSF penetration and changes in ISR biomarkers. Denali expected enrollment progress in 2024.
- SAR443820/DNL788: Sanofi reported in February 2024 that the Phase 2 ALS HIMALAYA study did not meet its primary endpoint. The MS Phase 2 study continued; detailed ALS results were expected at a future scientific forum.
- TAK-594/DNL593 for FTD-GRN: Enrollment and dosing in the patient portion of the Phase 1/2 study were voluntarily paused after two serious infusion-related reactions, including one Grade 3 event. Denali planned protocol changes, including premedication, before resuming.
- Other programs: DNL126 dosing in a Phase 1/2 study for MPS IIIA began in January 2024, with biomarker proof-of-concept and safety data expected in late 2024. Development of TAK-920/DNL919 for Alzheimer’s disease was discontinued in 2023 after safety signals of moderate, reversible hematologic effects at the highest tested dose and consideration of the treatment landscape. Eclitasertib’s CLE study was discontinued after missing its primary endpoint; its UC Phase 2 study continued.
- Denali expected to continue significant operating losses and R&D investment and has no product revenue. Key risks include clinical and regulatory failure or delay, trial enrollment and safety issues, dependence on partners and contract manufacturers, manufacturing scale-up, competition, intellectual-property challenges, reimbursement and pricing constraints, and the possibility that capital is consumed faster than expected.
- On February 27, 2024, Denali announced a private placement expected to generate approximately $499.7 million gross, subject to closing conditions. It comprised common shares and pre-funded warrants; the filing said proceeds were intended for R&D, BBB-platform expansion, working capital and general corporate purposes. This financing was subsequent to year-end, and its closing and dilution effects should be verified.
- The company reported no material litigation and received unqualified audit opinions on its financial statements and internal control over financial reporting. The auditor identified accrued and prepaid R&D costs as a critical audit matter, citing estimation of services performed using third-party data.
Most important facts for investors to verify
- Standalone Q4 2023 results, which are not clearly provided in this annual filing.
- Closing, net proceeds and fully diluted share impact of the announced $499.7 million PIPE, including exercise or conversion of the pre-funded warrants.
- COMPASS enrollment and subsequent DNL310 clinical, safety and regulatory updates; distinguish biomarker changes and exploratory outcomes from clinical benefit and approval evidence.
- Detailed HIMALAYA ALS efficacy and safety results, and progress in the ongoing DNL788 MS study.
- Whether TAK-594/DNL593 resumes dosing under its revised protocol and whether infusion-related risks recur.
- Cash burn, collaboration receipts and commitments, including the $75.0 million BIIB122 study funding and the timing of future milestone-triggered payments.
- Progress, cost and operational readiness of the Salt Lake City clinical manufacturing facility, which Denali expected to begin operating in 2024.